Centro Médico Teknon
| Turchia | Austria | Spagna | |
| Terapia radiante per sarcomi | da $3,250 | da $18,000 | da $8,000 |
| Radioterapia per il cancro colorettale | da $7,000 | da $12,000 | da $10,000 |
| Chemioterapia per carcinoma mammario | da $1,200 | da $15,000 | da $3,500 |
| Asportazione del rabdomiosarcoma | da $15,000 | da $30,000 | da $35,000 |
| Trattamento complesso del rabdomiosarcoma | da $45,000 | - | - |
Il medico è un oncologo pediatrico premiato, specializzato in sarcomi ossei e dei tessuti molli. Come capo del Dipartimento di Ematologia Oncologica presso Sant Joan De Déu, un ospedale pediatrico leader in Europa, il medico fornisce trattamenti per neuroblastomi, gliomi, sarcomi di Ewing e tumori di Wilms.<\/p>
Formatosi negli Stati Uniti, il medico ha completato borse di studio in ematologia oncologica pediatrica e patologia molecolare del cancro pediatrico presso Weill Cornell Medicine e Memorial Sloan Kettering Cancer Center. Il medico ha scritto oltre 70 articoli e ha sviluppato un trattamento non radiativo per i gliomi del midollo spinale.<\/p>
Il medico possiede una laurea in Medicina presso l'Università Complutense di Madrid e un dottorato presso l'Università di Barcellona. Specializzandosi in Ematologia e Oncologia Pediatrica presso l'Università del Maryland, il medico è esperto nel trattamento di tumori ossei e cerebrali, nonché di leucemia e malattie ematologiche.<\/p>
Con oltre due decenni di esperienza, il medico attualmente dirige l'Unità di Ematologia e Oncologia Pediatrica presso l'Ospedale HM Montepríncipe, concentrandosi sulla cura di bambini e adolescenti. In precedenza, il medico ha ricoperto la stessa posizione presso l'Ospedale Universitario Clínica San Rafael ed è autore di numerose pubblicazioni scientifiche.<\/p>
Il medico è uno specialista esperto in ematologia oncologica pediatrica e un neurochirurgo pediatrico di spicco in Spagna. Con oltre 30 anni di esperienza pratica, il medico guida l'Unità di Ematologia e Oncologia Pediatrica presso HM Hospitales, concentrandosi su gravi malattie ematologiche e cancerose nei bambini e negli adolescenti.<\/p>
Il medico è specializzato nella diagnosi e nel trattamento dei disturbi ematologici e cancerosi, in particolare nei sistemi eritrocitario, mieloide e linfoide. Il medico serve come consulente per l'OMS e l'UNESCO ed è coinvolto in attività di insegnamento e ricerca.<\/p>
Le credenziali educative includono lauree presso l'Universidad Complutense de Madrid, l'Università di Barcellona e l'Università del Maryland.<\/p>
Il medico è un oncologo pediatrico con 37 anni di esperienza, specializzato nel trattamento dei disturbi del sangue e nell'esecuzione di procedure come i trapianti di midollo osseo e la terapia ablativa. Attualmente, il medico è Capo dell'Emato-Oncologia Pediatrica presso l'Ospedale Universitario Quironsalud Madrid.<\/p>
Con un prolifico curriculum accademico, il medico ha curato 14 libri, contribuito a 75 capitoli di libri e presentato a oltre 200 conferenze. Il medico è membro di diverse associazioni professionali, tra cui l'Associazione Spagnola di Ematologia Pediatrica e l'Associazione Spagnola di Oncologia Pediatrica.<\/p>
Il medico tratta un'ampia gamma di condizioni, tra cui leucemia, linfoma, mieloma multiplo e vari disturbi ematologici e autoimmuni.<\/p>
Spanish hospitals such as SJD Barcelona Children’s Hospital and Clinica Universidad de Navarra specialize in rhabdomyosarcoma. These centers offer advanced molecular diagnostics and proton therapy within JCI-accredited facilities. Specialized pediatric oncologists focus on limb-preserving surgeries and targeted therapy for rare pediatric soft tissue sarcomas.
Bookimed Expert Insight: Quality signals for rare sarcomas are often found in the clinic's research capacity and patient volume. While Centro Médico Teknon serves 10,000 patients annually with JCI-certified care, SJD Barcelona treats 450,000 patients and maintains a dedicated molecular laboratory. This volume allows surgeons like Dr. Jaume Mora Graupera to manage complex cases that smaller facilities rarely see.
Patient Consensus: Families emphasize that traveling to a tertiary referral center is vital for rare tumors. They note that having a multidisciplinary tumor board and a specialist pathology review provides much-needed peace of mind during diagnosis.
Standard treatment options in Spanish clinics include multimodal approaches combining surgery, chemotherapy, and high-precision radiation. Specialized centers utilize diagnostic tools like PET-CT and MRI to stage sarcomas. Facilities often prioritize function preservation using targeted proton therapy and robotic-assisted tumor resections within JCI-accredited hospitals.
Bookimed Expert Insight: Spanish oncology centers like Clinica Universidad de Navarra report exceptional success with a 95% limb preservation rate for sarcomas. This outcome stems from a multidisciplinary approach where surgeons and oncologists prioritize saving function alongside cancer control. Choosing a certified sarcoma center in Spain is vital for rare diagnoses. These facilities often provide access to clinical trials and advanced proton beam therapy, which are not available in standard general hospitals.
Patient Consensus: Patients emphasize the importance of starting with chemotherapy to reduce tumor size before any surgery. They often note that a long surveillance period with repeated scans is the most challenging physical and emotional phase of recovery.
Relapsed or refractory rhabdomyosarcoma is treated with salvage chemotherapy, surgical resection, and radiation therapy. Spanish oncology centers frequently utilize regimens like Vincristine, Irinotecan, and Temozolomide. Specialist centers like SJD Barcelona Children Hospital also offer clinical trials and molecularly targeted immunotherapy for advanced cases.
Bookimed Expert Insight: Spain stands out for pediatric sarcoma care because of the high concentration of JCI-accredited centers in Barcelona and Madrid. For example, Clinica Universidad de Navarra reports a 95% limb preservation rate. This suggests that Spanish specialists prioritize functional recovery alongside tumor removal. When choosing a clinic, patients should look for those like SJD Barcelona Children Hospital that integrate active molecular research labs into their clinical practice.
Patient Consensus: Patients emphasize the need for a full record of prior treatments since previous radiation limits current options. They note that survival goals must be clarified early to choose between aggressive trial therapies or symptom-focused care.
Proton therapy provides precise radiation by eliminating the exit dose in healthy tissue. This technology protects developing organs in growing children. It significantly reduces long-term complications for tumors in sensitive areas like the head or pelvis. Treatment preserves growth, vision, and cognitive functions.
Bookimed Expert Insight: While Spain has 83 medical centers, specialized pediatric oncology and proton therapy are concentrated in specific hubs. Clinica Universidad de Navarra is a leading sarcoma center with a 95% limb preservation rate. Families should verify if tumors near the optic nerve or brain are eligible for the Proton Therapy Centre Quironsalud in Madrid. This facility specifically focuses on research-driven innovation to minimize late-stage side effects in children.
Patient Consensus: Patients note it is important to ask which specific late effects protons might reduce. They emphasize that while cure rates are similar to standard therapy, the primary goal is protecting quality of life decades later.
Spanish surgical teams achieve 95% limb preservation rates for complex sarcoma cases. Specialist centers prioritize multidisciplinary protocols to avoid amputation while ensuring clear margins. These outcomes are supported by advanced diagnostics like PET-CT and the integration of highly specialized pediatric and adult oncology units.
Bookimed Expert Insight: Spanish oncology centers like Clinica Universidad de Navarra and SJD Barcelona Children’s Hospital function as specialized hubs where high patient volumes drive better outcomes. Our data shows Clinica Universidad de Navarra serves over 140,000 patients yearly. This concentration of expertise allows surgeons to perform limb-sparing procedures even when tumors are near major nerves or vessels.
Patient Consensus: Patients note that limb preservation is most successful when tumors respond well to initial therapy. They emphasize that while function is saved, long-term rehabilitation is often necessary to manage stiffness.
Treatment planning for international pediatric patients involves a structured remote evaluation before travel. Specialized Spanish oncology centers review medical dossiers to determine clinical feasibility. A multidisciplinary tumor board then outlines a preliminary care pathway. This process ensures medical and logistics readiness for the child.
Bookimed Expert Insight: Spanish pediatric centers like SJD Barcelona Children’s Hospital often require pathology slide reviews. This step is critical for rhabdomyosarcoma to confirm tumor subtypes before travel. Clinica Universidad de Navarra reports a 95% limb preservation rate for sarcomas. This suggests their planning focus heavily prioritizes functional outcomes through specialized surgical techniques.
Patient Consensus: Parents emphasize that the first phase involves diagnostic confirmation before therapy begins. They note the importance of sending all imaging and records early to avoid treatment delays.